REDX.Lライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (1 5月 2024 @ 01:28):

Stats
本日の出来高	20.48M
平均出来高	838 041
時価総額	58.35M
EPS	£-0.0370 ( Q4 \| 2023-09-30 )
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-1.500 (Sector) 0 (Industry) 0
ATR14	£2.03 (13.52%)

AMYT.L -11.73%

APH.L -0.13%

AVCT.L -1.49%

AZN.L -0.45%

BMK.L 7.59%

BVXP.L -2.16%

C4XD.L 27.32%

CIR.L 0.00%

CLIN.L 0.11%

DEST.L -2.51%

DPH.L 0.05%

EAH.L 3.40%

ERGO.L 0.15%

ETX.L -6.74%

EVG.L 2.25%

FAB.L -1.59%

FARN.L -5.98%

FUM.L 0.27%

GDR.L 1.10%

GNS.L 1.45%

GSK.L -0.52%

HCM.L -0.36%

HEMO.L -2.66%

HIK.L -0.53%

IMM.L -1.15%

INDV.L 0.00%

IXI.L -5.25%

MTPH.L 1 794.74%

MXCT.L -2.17%

N4P.L -4.71%

NCYT.L -2.42%

NFX.L -5.00%

OBD.L 3.33%

OKYO.L -24.32%

ONC.L 0.45%

OPTI.L -3.63%

OVB.L -2.22%

OXB.L 2.58%

PRM.L -4.82%

PRTC.L 0.98%

PYC.L -6.25%

REDX.L 31.58%

RENE.L -2.17%

SAR.L 8.67%

SCLP.L -1.86%

SLN.L -0.93%

SNG.L 3.48%

STX.L 2.70%

TILS.L 8.33%

TRX.L -1.15%

VAL.L 0.00%

VEC.L 0.00%

ボリューム相関

長: -0.34 (neutral)

短: 0.93 (very strong)

Signal:(57.69) Expect same movement, but be aware

Redx Pharma PLC 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Redx Pharma PLC 相関 - 通貨/商品

0.64
( weak )

0.50
( neutral )

0.66
( moderate )

-0.01
( neutral )

-0.63
( weak negative )

0.11
( neutral )

Redx Pharma PLC 財務諸表

Annual	2023
収益:	£4.20M
総利益:	£3.24M (77.15 %)
EPS:	£-0.0990

FY	2023
収益:	£4.20M
総利益:	£3.24M (77.15 %)
EPS:	£-0.0990

FY	2022
収益:	£18.69M
総利益:	£18.69M (100.00 %)
EPS:	£-0.0612

FY	2021
収益:	£10.04M
総利益:	£0.00 (0.00 %)
EPS:	£-0.127

Financial Reports:

No articles found.

Redx Pharma PLC Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Redx Pharma PLC

Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company also develops RXC004, a porcupine inhibitor that is in Phase II clinical trial for targeted therapy of Wnt-ligand driven cancer; and RXC007, an oral selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor for the treatment of fibrotic diseases. In addition, it develops gastrointestinal targeted ROCK inhibitor to treat crohn's disease-associated fibrosis; discoidin domain receptors (DDRs) inhibitor for the treatment of multiple fibrotic conditions; and RXC006, a porcupine inhibitor targeting fibrotic diseases, including idiopathic pulmonary fibrosis. The company has a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase pathway. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.